Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab

• DOI: 10.1016/j.jaad.2003.11.044
• Publication Date: 2004-04-10T10:51:45Z
• Authors: Adam C Esser; Andy Abril; Scott Fayne; John A Doyle
• Keywords: Skin Neoplasms; Antibodies, Monoclonal; Infliximab; 3. Good health; Arthritis, Rheumatoid; Keratoacanthoma; 03 medical and health sciences; 0302 clinical medicine; Antirheumatic Agents; Carcinoma, Squamous Cell; Humans; Female; Aged

Infliximab, a chimeric mouse-human monoclonal antibody, blocks the action of tumor necrosis factor-alpha and is a highly effective treatment for several inflammatory disorders, including inflammatory bowel disease and rheumatoid arthritis. Although safety data are encouraging, immunosuppressive sequelae may result. We report the acute development of multiple squamous cell carcinomas and keratoacanthomas in a patient receiving infliximab for rheumatoid arthritis.